Brookfield Corp’s Altimmune ALT Stock Holding History

Brookfield Corp’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-47,785	Closed	-$202K	–	592
2023 Q1	$202K	Buy	+47,785	New	+$568K	﹤0.01%	659
2021 Q4	–	Sell	-26,593	Closed	-$301K	–	624
2021 Q3	$301K	Buy	+26,593	New	+$323K	﹤0.01%	488

Other funds holding ALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brookfield Corp's ALT Position: Q2 2023 in Review

Brookfield Corp sold out of Altimmune (ALT) in Q2 2023, closing a stake of 47,785 shares — an estimated $202K sold.

Brookfield Corp first reported a position in ALT in Q3 2021 and held it in 2 quarters. The position peaked at $301K in Q3 2021. 119 funds tracked by Wall St. Rank hold ALT as of Q2 2023.

Brookfield Corp reported no remaining Altimmune position as of Q2 2023 after selling out during the quarter.
Brookfield Corp sold 47,785 Altimmune shares in Q2 2023, an estimated $202K.
Brookfield Corp first reported a position in Altimmune in Q3 2021 and held it in 2 quarters.
Brookfield Corp's Altimmune position peaked at $301K in Q3 2021.
119 funds tracked by Wall St. Rank held Altimmune as of Q2 2023.

Based on Brookfield Corp's 13F filing for Q2 2023, filed 14 Aug 2023.